Patents by Inventor Taisuke Katoh
Taisuke Katoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10787462Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: October 21, 2016Date of Patent: September 29, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takatoshi Yogo, Masato Yoshikawa, Morihisa Saitoh, Taisuke Katoh, Tomohiro Seki, Yoshihisa Nakada
-
Publication number: 20180319819Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: October 21, 2016Publication date: November 8, 2018Inventors: Takatoshi YOGO, Masato YOSHIKAWA, Morihisa SAITOH, Taisuke KATOH, Tomohiro SEKI, Yoshihisa NAKADA
-
Patent number: 9828357Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: GrantFiled: November 21, 2016Date of Patent: November 28, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro, Taisuke Katoh, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
-
Publication number: 20170096422Abstract: Provided is a compound having a superior PKC inhibitory action, and useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like, or a salt thereof. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a superior PKC inhibitory action, and is useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like.Type: ApplicationFiled: March 23, 2015Publication date: April 6, 2017Inventors: Tetsuya TSUKAMOTO, Yoshihisa NAKADA, Michiyo MOCHIZUKI, Takafumi TAKAI, Tomoya YUKAWA, Zenyu SHIOKAWA, Taisuke KATOH, Masaki SETOH, Ayumu SATO, Takafumi YUKAWA
-
Publication number: 20170066737Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20160326133Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: June 7, 2016Publication date: November 10, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20160326102Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Patent number: 8772277Abstract: The present invention provides a novel compound having a superior activity as an ERR-? modulator and useful as an agent for the prophylaxis or treatment of ERR-? associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 3, 2012Date of Patent: July 8, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Koji Ono, Yusuke Tominari, Taisuke Katoh, Kazuhiro Miwa, Atsushi Hasuoka, Shinichi Imamura
-
Publication number: 20130072467Abstract: The present invention provides a novel compound having a superior activity as an ERR-? modulator and useful as an agent for the prophylaxis or treatment of ERR-? associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: August 3, 2012Publication date: March 21, 2013Inventors: Shigemitsu MATSUMOTO, Koji Ono, Yusuke Tominari, Taisuke Katoh, Kazuhiro Miwa, Atsushi Hasuoka, Shinichi Imamura